- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00982384
Comprehensive Disease Management Program in Chronic Obstructive Pulmonary Disease (COPD) Patients in the Community (COPD_CDM)
Comprehensive Disease Management Program in COPD Patients in the Community: Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study objective is to evaluate the effectiveness of a comprehensive program among patients with advanced COPD, implemented by a multi-disciplinary team. The program consists of best care recommended in clinical guidelines, combined with disease management, compared to best care only.
The program will include designated COPD centers operated by multi-disciplinary teams (pulmonologists, nurse practitioners, physiotherapists, social workers and dietitians). Disease management will be provided in these centers by qualified designated nurses.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bat-Yam, Israel
- Bat-Yam COPD Center
-
Hadera, Israel
- COPD Center, Hadera
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 40 years or older
- Advanced COPD
Exclusion Criteria:
- Permanent tracheostomy
- Heart failure with significant left-ventricular dysfunction
- Severe other chronic disease
- Significant cognitive impairment, Drug or alcohol abuse, inability to cooperate
- No telephone or permanent address
- Bedridden
- Refusal to use telemonitoring equipment
- Participation in another clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Disease management
Comprehensive disease management in addition to best care according to clinical guidelines for COPD patients
|
Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients
|
Active Comparator: Best care
Best care according to clinical guidelines for COPD patients
|
Comprehensive care for COPD patients recommended in clinical guidelines
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hospital admission for acute exacerbation of COPD or all-cause mortality
Time Frame: Within 2 to 5 years after randomization
|
Within 2 to 5 years after randomization
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total days of hospitalization for acute exacerbations of COPD
Time Frame: Within 2 to 5 years after randomization
|
Within 2 to 5 years after randomization
|
Quality of life
Time Frame: Within 2 to 5 years after randomization
|
Within 2 to 5 years after randomization
|
Total number of acute exacerbations of COPD
Time Frame: Within 2 to 5 years after randomization
|
Within 2 to 5 years after randomization
|
Depression
Time Frame: Within 2 to 5 years after randomization
|
Within 2 to 5 years after randomization
|
Functional capacity
Time Frame: Within 2 to 5 years after randomization
|
Within 2 to 5 years after randomization
|
Spirometry parameters
Time Frame: Within 2 to 5 years after randomization
|
Within 2 to 5 years after randomization
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ofra Kalter - Leibovici, M.D., Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center
- Study Director: Gershon Fink, M.D., Clalit Health Services
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHEBA-09-7120-OK-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD)
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary Disease (COPD) | COPDUnited Kingdom
-
Elpen Pharmaceutical Co. Inc.Completed
Clinical Trials on Disease management
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
The University of Texas Health Science Center at...Department of Health and Human Services; Centers for Disease Control and Prevention and other collaboratorsCompleted
-
Hiroshima UniversityMinistry of Health, Labour and Welfare, JapanCompletedIschemic StrokeJapan
-
Air Liquide Santé InternationalITEC Services; Lincoln Medical and Mental Health CenterCompletedChronic Obstructive Pulmonary Disease (COPD)France, Spain, Germany, Italy
-
Icahn School of Medicine at Mount SinaiAgency for Healthcare Research and Quality (AHRQ)CompletedCongestive Heart Failure (CHF) | Systolic DysfunctionUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedChemotherapy Induced Nausea and Vomiting